Total mortality · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
Hyperfractionated/accelerated radiotherapy showed no clear difference in total mortality compared with conventional (standard) fractionation radiotherapy; GRADE not reported.
1 finding from 1 review
Total mortality · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
Pre-operative and post-operative radiotherapy showed no clear difference in total mortality compared with post-operative radiotherapy alone; GRADE not reported.
1 finding from 1 review
HR 0.67 [0.35, 1.28]
1 study
GRADE not reported
Altered fractionation radiotherapy plus chemotherapy vs Chemoradiotherapy with standard (conventional) fractionation
Outcome not reported · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
The review found no eligible studies for this question.
1 finding from 1 review
Disease-free survival · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
1 finding from 1 review
Accelerated vs conventional, disease free survival: both trials reported this, but substantial clinical and statistical heterogeneity (P = 0.0004, I2 = 92%) meant a pooled analysis was not reported (Analysis 1.3).
2 studies
GRADE not reported
Disease-free survival · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
1 finding from 1 review
Locoregional control · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
Pre-operative radiotherapy (plus surgery) showed no clear difference in locoregional control compared with surgery alone; GRADE not reported.
1 finding from 1 review
RR 0.63 [0.28, 1.46]
1 study
GRADE not reported
Altered fractionation radiotherapy vs Chemoradiotherapy (concurrent, standard fractionation)
Outcome not reported · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
The review found no eligible studies for this question.
1 finding from 1 review
Readmission for phototherapy for hyperbilirubinemia · newborns for hyperbilirubinemia
Summary of findings table ‐ Transcutaneous bilirubin (TcB) screening probably leads to lower readmission for phototherapy for hyperbilirubinemia compared with visual assessment (moderate certainty).
1 finding from 1 review
Exchange transfusion · newborns for hyperbilirubinemia
Summary of findings table ‐ Transcutaneous bilirubin (TcB) screening showed no clear difference in exchange transfusion compared with visual assessment (low certainty).
1 finding from 1 review
Phototherapy before hospital discharge · newborns for hyperbilirubinemia
Summary of findings table ‐ Transcutaneous bilirubin (TcB) screening probably leads to higher phototherapy before hospital discharge compared with visual assessment (moderate certainty).
1 finding from 1 review
Acute bilirubin encephalopathy · newborns for hyperbilirubinemia
Summary of findings table ‐ Transcutaneous bilirubin (TcB) screening showed no clear difference in acute bilirubin encephalopathy compared with visual assessment (low certainty).
1 finding from 1 review
Economic outcomes: Cost of care · newborns for hyperbilirubinemia
1 finding from 1 review
Clinical improvement (dichotomous) · active EoE patients
Corticosteroids may leads to higher clinical improvement (dichotomous) compared with placebo (low certainty).
1 finding from 1 review
Histological improvement (dichotomous) · inactive EoE patients
Corticosteroids probably leads to higher histological improvement (dichotomous) compared with placebo (moderate certainty).
1 finding from 1 review
Clinical improvement (continuous) · inactive EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Histological improvement (dichotomous) · inactive EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Histological improvement (continuous) · inactive EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (dichotomous) · inactive EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (continuous) · inactive EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · inactive EoE patients
It is very uncertain whether leukotriene receptor antagonist changes withdrawals due to adverse events at 26 weeks compared with placebo (very low certainty).
1 finding from 1 review